Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light

University of California (UC) Davis

Status: Completed

Conditions: Sun Damaged Skin

Treatments: Drug: Zinc Oxide and Avobenzone

Study type: Interventional

Funder types: Other

Identifiers

NCT05865431

1042064

Details and patient eligibility

About

The objective of this study is quantification of singlet oxygen species in the skin after exposure to Ultraviolet A (UVA) light

Full description

Ultraviolet (UV) radiation can lead to skin damage and cancer. Ultraviolet A (UVA) irradiation is 10 to 100 times more abundant in natural sunlight than ultraviolet B (UVB), thus human skin is exposed to more UVA irradiation daily.UVA irradiation is not completely filtered by clothing and it penetrates deeper into the dermis than UVB, potentially causing more damage. It is believed that skin cancer, photo aging, and skin immunomodulation are mediated by the reactive oxygen species (ROS) that are generated in response to UV radiation. Singlet oxygen (1O2) is one type of ROS. The aim of this study is to quantify the level of singlet oxygen generated in the skin after exposure to UVA radiation. Previous studies have used low dose ultraviolet A1(UVA1) irradiation of 20 J/cm2, which mimics exposure to strong sunlight of approximately two hours. This study will use UVA doses equivalent to or less than what humans are exposed to in daily life. Additionally, the aim is to quantify singlet oxygen produced in individuals of various skin types before and after application of sunscreens containing zinc oxide and avobenzone (sun protection factor 30). To our knowledge, there is no method for quantifying singlet oxygen in human skin after exposure to UVA light. This is a novel method that may help the investigators understand further the protective effects of various skin types, as well as sunscreens.

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects aged 18 years and older

Exclusion criteria

• Those who are currently smoking or have smoked within the past 3 years.
• Aspirin use
• Multivitamins and supplements that contain vitamin E
• Adults unable to consent
• Individuals who are not yet adults (infants, children, teenagers)
• Pregnant women
• Prisoners

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

17 participants in 1 patient group

Zinc Oxide, Avobenzone, No Product

Experimental group

Description:

Participants have zinc oxide, avobenzone, and no product applied to 3 different spots on the forearm and singlet oxygen is measured after UV exposure.

Treatment:

Drug: Zinc Oxide and Avobenzone